Clinical Trial Update: Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating trastuzumab-rezetecan with either pertuzumab or a nab-paclitaxel/carboplatin/trastuzumab/pyrotinib regimen after suboptimal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Pertuzumab (pertuzumab)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)
• Trastuzumab Rezetecan

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: HER2-positive Early Breast Cancer | Phase 2 | Status: RECRUITING